Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel Broad-Spectrum Combination Therapy Targeting WHO’s Priority Pathogens

ANT3310 is a novel, potent and specific inhibitor of bacterial Serine Beta-Lactamases (SBLs) which displays excellent inhibitory activity against both KPC and OXA carbapenemases. It will be administered intravenously in conjunction with meropenem, for treating hospital-acquired infections caused by Gram negative pathogens, including those that are carbapenem-resistant, notably carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant A. baumannii (CRAB), which are WHO Priority Pathogens.

ANTABIO Completes € 12.5M Series A

New investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017.

First publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor program

Antabio announces publication of a manuscript in Antimicrobial Agents and Chemotherapy: Discovery of a Novel Metallo-ß-Lactamase Inhibitor, which can Potentiate Meropenem Activity against Carbapenem-Resistant Enterobacteriaceae (currently available as an ePublication – https://www.ncbi.nlm.nih.gov/pubmed/29530861). This is the first publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor…

ANTABIO Announces Key Executive Appointments

Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, is pleased to announce the addition of four highly successful and accomplished biotech executives to the management team. These appointments come soon after the first closing of Antabio’s Series A financing round and notification that Antabio has been selected as one of 18 out of 368 international candidates for a CARB-X subsidy award of up to $8,9 million.

Menu